Overview

Study to Assess the Efficacy and Safety of Ryanodex as Adjuvant Treatment in Subjects With EHS

Status:
Completed
Trial end date:
2019-08-14
Target enrollment:
Participant gender:
Summary
A double-blind, parallel study of Ryanodex for the adjuvant treatment of exertional heat stroke (EHS) compared to current Standard of Care (SOC) for EHS.
Phase:
Phase 3
Details
Lead Sponsor:
Eagle Pharmaceuticals, Inc.
Treatments:
Dantrolene